强生获FDA批准皮下注射肺癌联合疗法

环球市场播报
Yesterday

  强生公司(JNJ)周五早盘上涨0.4%,该公司获得美国食品与药物管理局(FDA)批准:其RYBREVANT FASPRO(amivantamab与透明质酸酶组合)可与lazertinib联用,用于一线治疗EGFR突变非小细胞肺癌,实现5分钟皮下注射给药。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10